Amoxicillin/adverse effects; Anti-Inflammatory Agents, Non-Steroidal/adverse effects; Chemical and Drug Induced Liver Injury/epidemiology; Clavulanic Acid/adverse effects; Isoniazid/adverse effects; Liver Diseases/epidemiology; Adult; Causality; China/epidemiology; Comorbidity; Democratic People's Republic of Korea/epidemiology; Dietary Supplements/adverse effects; Enzyme Inhibitors/adverse effects; Female; Fluoroquinolones/adverse effects; France/epidemiology; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects; Iceland/epidemiology; Male; Protein-Tyrosine Kinases/metabolism; Republic of Korea/epidemiology; Spain/epidemiology; Tumor Necrosis Factor-alpha/adverse effects; United States/epidemiology

AIH; ALF; ALT; CNS; DI-AIH; DILI; DILIN; Drug Induced Liver Injury Network; FDA; Food and Drug Administration; HDS; HEV; HLA; IV; LTx; N-Acetylcysteine; NAC; NAFLD; TNF; ULN; acute liver failure; alanine aminotransferase; autoimmunelike hepatitis; central nervous system; drug-induced autoimmunelike hepatitis; drug-induced liver injury; hepatitis E virus; herbal and dietary supplement; human leukocyte antigen; intravenous; liver transplantation; miRNA; micro RNA; nonalcoholic fatty liver disease; tumor necrosis factor; upper limit of normal